An FDA advisory committee voted against loosening restrictions on peptides, triggering a sell-off in HIMS shares.
Shares of Hims & Hers Health (HIMS) fell over 11% after an FDA advisory panel delivered its first negative vote on loosening restrictions for a group of widely used peptides. The decision marks a setback for the company, which has been expanding into peptide-based treatments.
The panel, reviewing potential deregulation, voted against the proposal, with six members opposing the change. Peptides have gained popularity in wellness and anti-aging therapies, but regulatory hurdles remain a key risk for companies in the sector.
The decline reflects investor concerns over regulatory delays and potential limitations on HIMS’s growth strategy in the peptide market.